Innovative Epilepsy Research Presented by UCB at IEC Congress
UCB Presents Groundbreaking Research at the International Epilepsy Congress
UCB, a global biopharmaceutical leader, is excited to showcase its latest research and advancements in epilepsy treatment at the upcoming International Epilepsy Congress (IEC). This event is a vital platform for medical professionals to exchange insights and innovations in managing epilepsy, focusing on critical areas like developmental and epileptic encephalopathies (DEEs).
Commitment to Advancing Epilepsy Care
At the IEC, UCB will present 26 scientific abstracts, including two pivotal oral presentations. These presentations underline UCB's dedication to enhancing patient care for those living with epilepsy. The company’s research highlights data from an open-label extension study on FINTEPLA (fenfluramine), showcasing its long-term safety and effectiveness in treating conditions such as Dravet syndrome and Lennox-Gastaut syndrome.
Long-term Efficacy of FINTEPLA
This extensive study enrolled 412 patients who previously participated in fenfluramine trials. Remarkably, it reported no new or unanticipated safety concerns while demonstrating sustained positive outcomes. This aligns with UCB's objective to deepen understanding of epilepsy management and improve patient quality of life.
Understanding Diagnostic Challenges in DEEs
UCB's research also delves into the complexities of diagnosing DEEs. A qualitative study involving caregivers and healthcare professionals reveals significant diagnostic gaps in adult patients. This research posits that establishing a confirmed diagnosis can lead to more comprehensive care and ultimately enhance the quality of life for patients.
Addressing Real-World Impacts and Everyday Challenges
UCB emphasizes the importance of addressing the daily challenges faced by patients living with epilepsy. Another key area of focus is the unpredictable nature of seizures and their disruptive effects on patients and caregivers. Through a caregiver survey, UCB has gained insights into how frequent disruptive seizures can adversely affect the everyday lives of those caring for patients with DEEs.
Impact of Prolonged Seizures
Research shared at IEC will include findings on prolonged seizures and their significant effects on quality of life. Data indicates that patients exhibiting prolonged seizures often face greater seizure-related anxiety and experience intense worry about acute episodes. These findings may contribute to better management strategies aimed at preventing status epilepticus and other complications that necessitate emergency interventions.
Innovative Symposiums and Presentations
UCB will host a series of symposiums to discuss vital topics regarding DEEs. The agenda includes enhancing knowledge about the broader implications of DEEs on adult patients, improving diagnostic accuracy, and managing treatment pathways effectively.
Expert Panels and Presentations
Lead authors and experts from UCB will deliver presentations on various impactful topics, including barriers in diagnosing DEEs and a newly developed checklist intended for non-specialists. This initiative is designed to facilitate the diagnosis of Lennox-Gastaut syndrome, reinforcing the need for comprehensive diagnostic tools.
About UCB
UCB, headquartered in Brussels, Belgium, is at the forefront of biopharmaceutical innovation, particularly focused on severe diseases affecting the central nervous system and immune system. With an impressive workforce of around 9,000 strong across 40 countries, UCB generated €5.3 billion in revenue last year. The company is committed to transforming patient lives through ground-breaking research and development. UCB is publicly traded on Euronext Brussels under the symbol UCB.
Frequently Asked Questions
What is UCB's role in epilepsy treatment?
UCB is committed to advancing epilepsy therapies and conducting extensive research to improve treatment outcomes for patients.
What significant findings will UCB present at the IEC?
The company will present research on the safety and efficacy of FINTEPLA, as well as insights into the challenges of diagnosing DEEs.
Where is the International Epilepsy Congress being held?
The IEC is hosted in Lisbon, Portugal, providing a platform for global experts to share knowledge and research.
What is the significance of prolonged seizure research?
UCB's research on prolonged seizures aims to understand their impact on patients' daily lives and improve management strategies.
How does UCB focus on patient quality of life?
UCB prioritizes patient quality of life by deepening insights into treatment experiences and improving healthcare solutions.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.